Long-term impact of 10-valent pneumococcal conjugate vaccine among children <5 years, Uganda, 2014–2021
Saved in:
Main Authors: | Mercy Wendy Wanyana, Richard Migisha, Patrick King, Lilian Bulage, Benon Kwesiga, Daniel Kadobera, Alex Riolexus Ario, Julie R. Harris |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2025-01-01
|
Series: | PLOS Global Public Health |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11703042/?tool=EBI |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Impacts of the 13-Valent Pneumococcal Conjugate Vaccine in Children
by: Susanna Esposito, et al.
Published: (2015-01-01) -
Immunogenicity and safety of the 15-valent pneumococcal conjugate vaccine, a systematic review and meta-analysis
by: Gernot Wagner, et al.
Published: (2024-12-01) -
Protocol for a phase IV double-blind randomised controlled trial to investigate the effect of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine on pneumococcal colonisation using the experimental human pneumococcal challenge model in healthy adults (PREVENTING PNEUMO 2)
by: Tao Chen, et al.
Published: (2022-07-01) -
A population-based study on the burden of hospitalized pediatric pneumococcal disease in Taiwan before and after the introduction of 13-valent pneumococcal conjugate vaccine into the childhood immunization program in 2015
by: Ting-An Yen, et al.
Published: (2025-02-01) -
Serotype-specific serum immunoglobulin G at 18 months of age following one or two doses of a primary series of 10-valent or 13-valent pneumococcal conjugate vaccine and a booster dose at nine months of age: a randomized controlled study
by: Alane Izu, et al.
Published: (2025-12-01)